|Tested species reactivity||Human|
|Published species reactivity||Not Applicable|
|Host / Isotype||Mouse / IgG1|
|Storage buffer||PBS with BSA|
|Contains||0.1% sodium azide|
|Storage Conditions||4° C, store in dark|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay-Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Flow Cytometry (Flow)||See 1 publications below|
Commonly used, FITC conjugates provide relatively high absorptivity, excellent fluorescence quantum yield, and good water solubility.
CD3 complex is crucial in transducing antigen-recognition signals into the cytoplasm of T cells and in regulating the cell surface expression of the TCR complex. T cell activation through the antigen receptor (TCR) involves the cytoplasmic tails of the CD3 subunits CD3 gamma, CD3 delta, CD3 epsilon and CD3 zeta. These CD3 subunits are structurally related members of the immunoglobulins super family encoded by closely linked genes on human chromosome 11. The CD3 components have long cytoplasmic tails that associate with cytoplasmic signal transduction molecules. This association is mediated at least in part by a double tyrosine-based motif present in a single copy in the CD3 subunits. CD3 may play a role in TCR-induced growth arrest, cell survival and proliferation. The CD3 antigen is present on 68-82% of normal peripheral blood lymphocytes, 65-85% of thymocytes and Purkinje cells in the cerebellum. It is never expressed on B or NK cells. Decreased percentages of T lymphocytes may be observed in some autoimmune diseases.
Analyte Specific Reagent
|Not Applicable||Not Cited||
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.
CD0301 was used in flow cytometry to assess intrahepatic delivery of anti-CEA chimeric antigen receptor-modified T cells through percutaneous hepatic artery infusions
|Katz SC,Burga RA,McCormack E,Wang LJ,Mooring W,Point GR,Khare PD,Thorn M,Ma Q,Stainken BF,Assanah EO,Davies R,Espat NJ,Junghans RP||Clinical cancer research : an official journal of the American Association for Cancer Research (21:3149)||2015|